<DOC>
	<DOC>NCT01537640</DOC>
	<brief_summary>Primary Objective: To determine and compare the pharmacokinetic (PK) profiles of 2 different SAR231893 (REGN668) drug products after administration of a single subcutaneous (SC) dose Secondary Objective: To determine and compare the safety and tolerability of the 2 SAR231893 (REGN668) drug products after administration of a single SC dose</brief_summary>
	<brief_title>Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects</brief_title>
	<detailed_description>The duration of the study for each subject is 8-11 weeks broken down as follows: - Screening: 2 to 21 days, - Treatment: 1 day (2 overnight stays at the study site), - Follow-up: up to 2 months after dosing.</detailed_description>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Healthy male and female subjects between 18 and 45 years of age Exclusion criteria: Presence or history of drug hypersensitivity or allergic disease History or presence of dermatological disorders Fever or persistent chronic or active recurring infection requiring treatment within 4 weeks prior to screening, or history of frequent recurrent infections Prior opportunistic infections within 6 months before inclusion History or presence of listeriosis or tuberculosis Any vaccination within 3 months (1 month for influenza vaccine) before inclusion Any biologics given within 4 months before inclusion Recent history of a parasitic infection or travel to a parasitic endemic area within 6 months prior to screening The above information is not intended to contain all considerations relevant to a subject's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>